Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Juan Carlos Caballero-BerrocalJulio DávilaMaría López-PavíaEsperanza SuchTeresa BernalFernando RamosMarisa CalabuigJesús María Hernández SánchezHelena PomaresMercedes Sánchez BarbaMaría AbáigarBernardo GonzálezBrayan MerchánReyes Sancho-TelloMarta CallejasCarolina Muñoz-NovasCarlos CerveróGuillermo SanzJesús María Hernández RivasMaría Díez Campelo

Published in: Therapeutic advances in hematology (2024)

This large study confirms the beneficial effect of ESAs and the adverse effect of somatic mutations in patients with LR-MDS.

Keyphrases

copy number
metabolic syndrome
adverse drug
glycemic control
genome wide
electronic health record